title: A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
  
  
  METHODS
  This was a phase II, multicenter, open-label, single-arm trial in treatment-naïve patients with stage IIIA and IIIB LA-NSCLC. After three induction cycles with gemcitabine 1250 mg/m(2) plus cisplatin 80 mg/m(2), two concurrent chemoradiotherapy cycles with gemcitabine 300 mg/m(2), cisplatin 80 mg/m(2), and radiotherapy (63 Gy) were administered. The primary endpoint was response rate after induction chemotherapy followed by concurrent chemoradiotherapy. Secondary endpoints included time to progressive disease (TtPD), overall survival (OS), and safety.
  
  
  RESULTS
  Overall, 49 patients (median age 63.4 years; 73.5% male; Karnofsky performance status scores of 80, 85, 90, and 100 [16.3%, 2.0%, 49.0%, and 32.7%, respectively]; disease stage IIIA or IIIB 28.6% and 71.4%, respectively) were enrolled and treated. Response rate was 38.8% (95% confidence interval [CI] 25.2-53.8%). Median TtPD was 11.4 months (95% CI 9.4-12.9). Median OS was 21.8 months (95% CI 17.5-26.0), with 1- and 2-year survival rates of 70.8% and 43.7%, respectively. Overall, six patients discontinued from study treatment due to adverse events (AEs), of which two were serious AEs. The most relevant grade 3/4 AEs were neutropenia and thrombocytopenia in induction chemotherapy and chemoradiotherapy, and grade 3 events related to radiation in acute chemoradiotherapy, e.g. dysphagia, radiation pneumonitis, and radiation esophagitis.
  
  
  CONCLUSIONS
  Induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine (300 mg/m(2)) and cisplatin was associated with acceptable toxicity. The observed median OS time was 21.8 months. Response evaluation was difficult as in many cases it was not possible to differentiate tumor progression from local radiofibrosis.
authors: AZ Turnhout, Rubensstraat 166, 2300 Turnhout, Belgium.
authors: Peter
authors: P
authors: Driesen
authors: Marc
authors: M
authors: Lambrechts
authors: Kees
authors: K
authors: Kraaij
authors: Victoria
authors: V
authors: Soldatenkova
authors: Nadia
authors: N
authors: Chouaki
authors: Benoit
authors: B
authors: Colinet
keywords: LA-NSCLC; concurrent chemoradiotherapy; gemcitabine
references: J Clin Oncol. 2007 May 1;25(13):1698-704
references: 17404369
references: J Clin Oncol. 2002 Feb 1;20(3):804-10
references: 11821464
references: Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
references: 7713792
references: Lung Cancer. 2009 May;64(2):187-93
references: 18804894
references: J Clin Oncol. 2002 Oct 15;20(20):4191-8
references: 12377962
references: J Clin Oncol. 2010 May 1;28(13):2181-90
references: 20351327
references: Ann Oncol. 2006 Mar;17(3):473-83
references: 16500915
references: Clin Lung Cancer. 2009 May;10(3):180-6
references: 19443338
references: BMJ. 1995 Oct 7;311(7010):899-909
references: 7580546
references: J Clin Oncol. 2008 Dec 10;26(35):5755-60
references: 19001323
references: J Clin Oncol. 2005 Sep 1;23(25):5883-91
references: 16087941
references: Clin Lung Cancer. 2006 Sep;8(2):116-21
references: 17026812
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437